VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identificatio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sarah Low, Haixia Wu, Kavita Jerath, Annette Tibolla, Birgit Fogal, Rebecca Conrad, Deborah Webb, Margit MacDougall, Steven Kerr, Valentina Berger, Rajvee Dave, Jorge Villalona, Lynn Pantages, Jennifer Ahlberg, Hua Li, Diane Van Hoorick, Cedric Ververken, John Broadwater, Alisa Waterman, Sanjaya Singh, Rachel Kroe-Barrett
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis Group 2020-01-01
Colección:mAbs
Materias:
VHH Antibodies
GPCR
atherosclerosis
BI 655088
biophysical assessment
pharmacokinetic profile
Acceso en línea:https://www.tandfonline.com/doi/10.1080/19420862.2019.1709322
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares